PRECEPTORSHIP PROGRAMME

Transcription

1 esmo.org PRECEPTORSHIP PROGRAMME Gastrointestinal Tumours Multidisciplinary management, standards of care and future perspectives SINGAPORE OCTOBER 2016 Co-Chairs

2 Jean-Yves Douillard, Switzerland Daniela Aust, Germany Hans-Rudolf Raab, Germany Francis Seow-Choen, Singapore Yung-Jue Bang, South Korea Mark Saunders, United Kingdom Fabrice Caillol, France Jimmy So, Singapore Fatima Carneiro, Portugal Thorsten Götze, Germany Claus-Henning Köhne, Germany To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings To understand the importance of pathology and histoprognostic factors To learn about the management of patients after progression, side-effects of treatments, and in special situations To learn the fundamental of epidemiology, etiology, pathogenesis, molecular events and ethnic patterns as contributing factors to heterogeneity in gastric cancer To understand the essentials in the diagnosis and multidisciplinary treatment in gastric cancer To learn about the advances in the treatment and novel targets in gastric cancer The programme of this event has been accredited with Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org. This event is supported by an unrestricted educational grant from ESMO Head Office Education Department Via Luigi Taddei Lugano - Viganello Switzerland

3 09:00-09: :15 10:50 95 Welcome and introduction Session 1 Early colorectal cancer 30 Histo-prognostic factors: what histopathology has to offer for clinical decisionmaking 20 State of the art: standard of surgical practice for resectable colorectal cancer (special issues on rectal cancer) Daniela Aust, DE 30 State of the art: standard(s) of radio/chemotherapy for rectal cancer Mark Saunders, UK 15 Adjuvant chemotherapy of rectal cancer 10:50-11: 11:10 10 Coffee Break 11:10-13: Session 2 Adjuvant settings of colorectal cancer 30 Microsatellite instability and other molecular markers how useful are they? Daniela Aust, DE 30 Adjuvant treatment for colon cancer III 30 Adjuvant treatment of stage II: which patients to treat? 13:10-14:30 14:30 Lunch 14:30-16: Session 3 Metastatic colorectal cancer, liver limited metastases 30 Development of conventional chemotherapy in mcrc, BSC vs. chemo, biochemical modulation, oral fluoropyrimidines, development of combination chemotherapy and the review of the ESMO consensus conference on metastatic colorectal cancer 30 Resection of liver limited metastasis (resectable cases) - Upfront - After neo-adjuvant treatment - Repeated hepatectomy 30 Unresectable or borderline resectable chemotherapy +/- targeted agents 2x10 Participants clinical case discussion Faculty 16:20-17:00 17:00 Coffee Break

4 17:00-18:30 Session 4 Special clinical situations: mono- or oligometastatic disease 30 Treatment of metastatic disease confined to the peritoneum - Resection - HIPEC - PIPEC 30 Options of locoregional treatment of liver metastasis - Intra-arterial therapy - Chemo-embolisation - SIRT - Local radiation 30 Primary with synchroneous metastases 20:00 Dinner 08:30-9:45 75 Session 5 Metastatic colorectal cancer I 50 Chemotherapy and targeted agents in 1 st line 25 The role of maintenance, appropriate endpoints according to ESMO consensus 9:45-10: 10:15 15 Coffee Break 10:15-11:45 Session 6 Metastatic colorectal cancer II 30 What to do after 1 st line failure 30 Management of treatment related side effects - GI-Toxicity - Neuropathy - Skin toxicity - Hypertension - Hand-foot syndrome 11:45-12:30 45 Session 7 Anal canal tumours Chair : 30 Standard of care for anal canal squamous carcinomas Mark Saunders, UK 15 Salvage surgery of anal canal squamous carcinomas 12:30-13:30 13:30 Lunch

5 13:30-14:50 80 Session 1 Epidemiology, pathology and endoscopy of gastric cancer 20 Epidemiology (including GE junction) and clinical presentation Thosten Götze, DE 30 Endoscopy in gastric cancer: new imaging techniques, new treatment modalities (EMR, ESD) Fabrice Caillol, FR 30 Surgery for gastric and GE junction cancer, primary, palliative - where and when? Jimmy So, SG 14:50-15:2 15:20 Coffee Break 15:20-17: Session 2 Surgical, adjuvant and neoadjuvant treatment of gastric cancer 30 Neo- and adjuvant treatment for gastric cancer and GE junction cancer: the role of radiotherapy Mark Saunders, UK 30 Neo- and adjuvant treatment for gastric cancer: the role of chemotherapy Thorsten Götze, DE 30 Chemotherapy for metastatic disease Thorsten Götze, DE 4x10 Participants clinical case discussion Faculty 8:30-10:00 Session 3 Clinical discussions Yung-Jue Bang, KR 30 Pathology and carcinogenesis Fatima Carneiro, PT 10 Discussion Faculty 50 - Molecular events and classification in gastric cancer - Hereditary gastric cancer Fatima Carneiro, PT 10:00-10:30 10:30 Coffee Break 10:30-12: Session 4 Advanced disease Mark Saunders, UK 40 Biological targeted agents (including HER2, EGFR, angiogenesis) Yung-Jue Bang, KR 40 New targets (including cmet, FGF, mtor, PDL ) Yung-Jue Bang, KR 20 Case discussion based on ESMO recommendations/guidelines 12:40-12:50 10 Conclusion and farewell 12:50-13:5 13:50 Lunch Note: Each 10 minute slot for clinical case discussion includes 5 case presentation and 5 Q&A / panel discussion